0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
0-9
- 3D-structure
QLK2-CT-2002-01682
QLK2-CT-2001-01225A
- AbortionQLK2-CT-2001-01050
- AdenovirusQLK2-CT-2002-01432
- AdjuvantQLK2-CT-2001-02114
- adjuvantsQLK2-CT-2001-02103
- Adrenal functionQLK2-CT-2000-00589
- AdultsQLK2-CT-2002-01432
- AffinityQLK2-CT-2002-00620
- AgroinfiltrationQLK2-CT-2000-00739
- AIDSQLK2-CT-1999-00055QLK2-CT-1999-00609QLK2-CT-2000-00291QLK2-CT-2000-00773QLK2-CT-2000-01040QLK2-CT-2000-01431QLK2-CT-2000-01630QLK2-CT-2001-02360
- AIDS vaccineQLK2-CT-1999-01321QLK2-CT-2001-01316
- AlgorithmsQLK2-CT-2000-00294
- AllergyQLK2-CT-2000-00325
- Alveolar echinococcosisQLK2-CT-2001-01995
- AmpliconsQLK2-CT-1999-00055
- AMPSQLK2-CT-2000-00411
- Animal disease controlQLK2-CT-2002-01573
- Animal modelQLK2-CT-2001-00874QLK2-CT-2002-01034
- Animal model for hcvQLK2-CT-1999-00356
- Animal modelsQLK2-CT-1999-01044QLK2-CT-2001-00977QLK2-CT-2001-02103
- AnimalsQLK2-CT-2002-01146
- Anti-adhesionQLK2-CT-2002-01852
- Anti-infectivesQLK2-CT-2000-00543
- Anti-phospholipidQLK2-CT-2000-01166
- Anti-retroviral therapyQLK2-CT-2000-01431
- Anti-tumour immunotherapyQLK2-CT-2002-01112
- Anti-viral immunotherapyQLK2-CT-2002-01112
- Anti-viral moleculesQLK2-CT-2002-01691
- AntibioticQLK2-CT-2001-00873QLK2-CT-2001-00915
- Antibiotic combinationsQLK2-CT-2000-00411
- Antibiotic policiesQLK2-CT-2001-00915
- Antibiotic resistanceQLK2-CT-2000-00935QLK2-CT-2001-01339QLK2-CT-2001-01436QLK2-CT-2002-01146
- Antibiotic resistance transmissionQLK2-CT-2000-01624
- AntibioticsQLK2-CT-2002-00892
- AntibodiesQLK2-CT-2002-01399
- AntibodyQLK2-CT-1999-00772
- Antibody detectionQLK2-CT-2001-01632
- AntifungalsQLK2-CT-2001-02377
- AntigenQLK2-CT-1999-00359
- Antigen combinationsQLK2-CT-2002-01722
- Antigen deliveryQLK2-CT-2002-01249
- Antigen presentationQLK2-CT-2002-00620
- Antigen processingQLK2-CT-2001-01167QLK2-CT-2002-00700
- AntimetabolitesQLK2-CT-2000-00291
- AntimicrobialQLK2-CT-2001-01216
- Antimicrobial agentsQLK2-CT-2001-01339
- Antimicrobial drug resistanceQLK2-CT-2000-01404QLK2-CT-2000-01624
- Antimicrobial peptidesQLK2-CT-2000-00411QLK2-CT-2002-01001
- Antimicrobial resistance genesQLK2-CT-2002-00843
- AntimicrobialsQLK2-CT-2000-00543
- Antiretroviral therapyQLK2-CT-2002-01299
- Antiretroviral therapy (ART)QLK2-CT-2000-00150
- AntiviralQLK2-CT-2002-01719
- Antiviral agentsQLK2-CT-2000-01535QLK2-CT-2000-01630QLK2-CT-2001-01120
- Antiviral compoundsQLK2-CT-2001-01451
- Antiviral drugsQLK2-CT-2001-01225QLK2-CT-2002-01329
- Antiviral peptidesQLK2-CT-2002-00810
- Antiviral therapiesQLK2-CT-2002-00954
- AntiviralsQLK2-CT-2001-00977QLK2-CT-2002-01358
- ApoptosisQLK2-CT-2002-01691
- AquacultureQLK2-CT-2000-01049QLK2-CT-2001-00844QLK2-CT-2002-00722QLK2-CT-2002-01546QLK2-CT-2002-01691
- ArenavirusQLK2-CT-2002-01358
- ArtesunateQLK2-CT-2001-01430
- ArthropodQLK2-CT-2002-01293
- ASFQLK2-CT-2001-02216
- Assay developmentQLK2-CT-2000-01630
- Attenuated and inactivated vaccinesQLK2-CT-2001-01722
- AttenuationQLK2-CT-1999-00014QLK2-CT-1999-00938
- AttractantQLK2-CT-2001-01236
- Atypical pneumoniaQLK2-CT-2000-00294
- AutoimmunityQLK2-CT-2002-01399
- AvermectinsQLK2-CT-2000-00809
- Avian colibacillosisQLK2-CT-2002-00944
- Avian influenzaQLK2-CT-2002-01454
B
- B cell responseQLK2-CT-2002-01329
- BabAQLK2-CT-2001-01216
- BabesiaQLK2-CT-2000-01166
- BacteriaQLK2-CT-1999-00938QLK2-CT-2000-01536QLK2-CT-2002-01146
- Bacterial conjugationQLK2-CT-2000-01624
- Bacterial dnaQLK2-CT-2000-00336
- Bacterial live carrierQLK2-CT-1999-00780
- Bacterial membraneQLK2-CT-2002-01001
- Bacterial pathogenicityQLK2-CT-2000-01536
- Bacterial pathogensQLK2-CT-2000-00935
- Bacterial virulenceQLK2-CT-2000-01404
- Bacterial virulence factorsQLK2-CT-2001-01200
- Bacterial_infectionQLK2-CT-2000-01126
- Bacterial_invasionQLK2-CT-2000-01126
- Bacterium-host interactionQLK2-CT-2002-00944
- BaculovirusQLK2-CT-2002-01249
- BBG2NaQLK2-CT-1999-01044
- Beauveria bassianaQLK2-CT-2001-01236
- Bio-mathematical modelsQLK2-CT-2000-00836
- BioassaysQLK2-CT-2000-00809
- BiobanksQLK2-CT-2001-01994
- BiochemistryQLK2-CT-2000-01761
- BioinformaticsQLK2-CT-2001-01120QLK2-CT-2001-02018
- Biological adjuvantsQLK2-CT-1999-00601
- Bioproduction technologies for ampsQLK2-CT-2000-00411
- BivalvesQLK2-CT-2002-01691
- BlockadeQLK2-CT-1999-00753
- Blood productsQLK2-CT-2001-00877
- Blood testQLK2-CT-2001-02380
- BluetongueQLK2-CT-2000-00611
- Bluetongue virusQLK2-CT-2001-01722
- Bone marrow transplantationQLK2-CT-2002-01112
- Bordetella pertussisQLK2-CT-2001-01819
- Borna diseaseQLK2-CT-2002-01358
- BorreliaQLK2-CT-2002-01293
- Bovine spongiform encephalopathyQLK2-CT-2000-00837
- Bovine spongiform encephalopathy (bse)QLK2-CT-2001-01924
- BrainQLK2-CT-2002-01628
- BrucellaQLK2-CT-1999-00014QLK2-CT-2002-00918
- BrucellosisQLK2-CT-2002-00918
- BVDVQLK2-CT-2002-01573
C
- CancerQLK2-CT-2001-01994
- CandidaQLK2-CT-2000-00795
- Candida albicansQLK2-CT-2001-01216QLK2-CT-2001-02377
- Carbohydrate bindingQLK2-CT-2002-01852
- CARPQLK2-CT-2001-01288
- Carrier stateQLK2-CT-2002-01719
- CattleQLK2-CT-2001-01050
- CD4QLK2-CT-2000-01431QLK2-CT-2002-01708
- CD4 T cells to HIV CD8 T cell to HIV QLK2-CT-2002-01299
- CD4 + T cell responseQLK2-CT-2002-01329
- CD8 + T cell responseQLK2-CT-2002-01329
- Cell binding assaysQLK2-CT-2001-01120
- Cell cultureQLK2-CT-2001-00977QLK2-CT-2001-01786QLK2-CT-2001-02085QLK2-CT-2002-01034
- Cell surface glycosylationQLK2-CT-2001-02377
- Cell wallQLK2-CT-2000-00795
- Cellular factorsQLK2-CT-2001-01225
- Cellular immune responsesQLK2-CT-1999-00780
- Cellular responsesQLK2-CT-1999-00799
- Central nervous systemQLK2-CT-1999-01215QLK2-CT-2002-00882
- Challenge experimentsQLK2-CT-2001-01819
- CharacterizationQLK2-CT-2000-01404
- Chemical library screeningsQLK2-CT-2001-02018
- ChemokineQLK2-CT-1999-00601
- ChemokinesQLK2-CT-2001-02103
- ChemotherapyQLK2-CT-2000-00291QLK2-CT-2002-01628
- ChickenQLK2-CT-2000-01126
- ChildrenQLK2-CT-2000-00150QLK2-CT-2002-01432
- Chimeric capsidsQLK2-CT-2000-01476
- Chlamydia pneumoniaeQLK2-CT-2002-00846
- Chloroquine resistanceQLK2-CT-2002-00774
- Chromatin immunoprecipitationQLK2-CT-2002-00954
- Chronic hepatitis bQLK2-CT-2000-01476
- Chronic liver diseaseQLK2-CT-2002-01329
- CidofovirQLK2-CT-2002-01432
- CircovirusQLK2-CT-1999-00002QLK2-CT-1999-00307
- Clade CQLK2-CT-2002-01431
- Classical swine feverQLK2-CT-2001-01346
- Classical swine fever virus (CSFV)QLK2-CT-2001-01374
- Clinical outcomeQLK2-CT-2000-00773
- Clinical trialsQLK2-CT-2000-00150QLK2-CT-2000-00836
- ClostridiumQLK2-CT-2001-01267
- CohortQLK2-CT-2000-00773QLK2-CT-2002-01613
- Combination therapyQLK2-CT-2001-02360
- Combinatorial librariesQLK2-CT-2001-01216QLK2-CT-2002-00892
- Comparative genomicsQLK2-CT-2001-02018
- CompensationQLK2-CT-2001-00873
- ComplementQLK2-CT-1999-01215QLK2-CT-2002-00882
- Computer modellingQLK2-CT-2002-01034
- Conjugation assayQLK2-CT-2000-01624
- Conjugation inhibitorQLK2-CT-2000-01624
- Consensus guidelinesQLK2-CT-2001-00915
- ConsumptionQLK2-CT-2001-00915
- Contagious neoplasiaQLK2-CT-2001-02380
- ControlQLK2-CT-2002-01358
- Control of infectious diseasesQLK2-CT-1999-00070QLK2-CT-1999-00228QLK2-CT-2000-00726
- Control systemQLK2-CT-2001-01236
- CoronavirusQLK2-CT-1999-00002QLK2-CT-2001-00874QLK2-CT-2002-00825
- Coronavirus vectorQLK2-CT-2002-01050
- CorticosteroidsQLK2-CT-2000-00589
- CostQLK2-CT-2001-00873
- Cowpea mosaic comovirusQLK2-CT-2000-00739
- Cowpox virusQLK2-CT-2002-01358
- Creutzfeldt-jacob disease (CJD)QLK2-CT-2001-01924
- Creutzfeldt-Jakob diseaseQLK2-CT-2000-00837QLK2-CT-2000-01709QLK2-CT-2001-01441QLK2-CT-2001-02248QLK2-CT-2002-01523
- Crohn's diseaseQLK2-CT-2001-01420
- CrustaceansQLK2-CT-2002-01691
- Crystal structureQLK2-CT-2001-01120QLK2-CT-2002-00887QLK2-CT-2002-00892
- CrystallographyQLK2-CT-2000-01761
- CTLQLK2-CT-1999-00318QLK2-CT-2002-01034
- CTL-stimulating vaccinesQLK2-CT-2002-00700
- Culicoides vectorsQLK2-CT-2001-01722
- Culicoides-borne diseasesQLK2-CT-2000-00611
- CytoadhesionQLK2-CT-2000-00109
- Cytochromes P450QLK2-CT-2001-02018
- CytokineQLK2-CT-1999-00601QLK2-CT-1999-01215QLK2-CT-2002-00882
- CytokinesQLK2-CT-2001-02103
- CytomegalovirusQLK2-CT-2002-00620QLK2-CT-2002-01112
D
- Data miningQLK2-CT-2000-01536
- DatabaseQLK2-CT-2000-00630
- DatabasesQLK2-CT-2000-01536
- Day-care centersQLK2-CT-2000-01020
- Defective virusesQLK2-CT-2002-01034
- DeliveryQLK2-CT-2002-00825
- DementiaQLK2-CT-2000-00837QLK2-CT-2002-01523
- Dendritic cellQLK2-CT-2002-01329
- Dendritic cell based vaccineQLK2-CT-1999-01215QLK2-CT-2002-00882
- Dendritic cellsQLK2-CT-2001-02103QLK2-CT-2002-00846QLK2-CT-2002-01112
- DengueQLK2-CT-2000-01787
- DeoxyQLK2-CT-2002-00887
- Dermanyssus gallinaeQLK2-CT-2001-01236
- DevelopmentQLK2-CT-1999-01293
- Development of new antimicrobial approachesQLK2-CT-2001-01200
- Development pharmacologyQLK2-CT-2000-01166
- DiabetesQLK2-CT-2001-01910
- DiagnosisQLK2-CT-1999-00445QLK2-CT-1999-00854QLK2-CT-2001-00844QLK2-CT-2001-00877QLK2-CT-2001-00977QLK2-CT-2001-01050QLK2-CT-2001-01267QLK2-CT-2001-01810QLK2-CT-2001-02216QLK2-CT-2002-00722QLK2-CT-2002-01546
- Diagnostic testQLK2-CT-2002-01546
- Diagnostic testsQLK2-CT-2000-00589QLK2-CT-2000-01709QLK2-CT-2001-01339QLK2-CT-2001-01441QLK2-CT-2001-01786QLK2-CT-2001-01819QLK2-CT-2001-02248
- DiagnosticsQLK2-CT-2002-01358QLK2-CT-2002-01573QLK2-CT-2002-01699
- Diagnostics of viral diseasesQLK2-CT-2000-00486
- DiarrhoeaQLK2-CT-1999-00938QLK2-CT-2002-01249
- DimerisationQLK2-CT-2000-00291
- DiphtheriaQLK2-CT-2000-00542
- Directed evolution of ampsQLK2-CT-2000-00411
- Discovery of new drugsQLK2-CT-2001-01200
- Disease controlQLK2-CT-2002-01546
- Disease resistanceQLK2-CT-2000-00726
- DisinfectionQLK2-CT-2002-01546
- DNAQLK2-CT-1999-00014QLK2-CT-2002-01431
- DNA chipQLK2-CT-2002-00944
- DNA chipsQLK2-CT-2002-01503
- DNA fingerprintingQLK2-CT-2000-00630QLK2-CT-2001-00915
- DNA markersQLK2-CT-2001-01631
- DNA pol III-inhibitorsQLK2-CT-2000-00634
- DNA sequence dataQLK2-CT-2001-01120
- DNA sequencingQLK2-CT-2001-01810
- DNA vaccinationQLK2-CT-2002-01304
- DNA vaccineQLK2-CT-2002-00617QLK2-CT-2002-01430
- DNA vaccinesQLK2-CT-1999-00601
- DNA-array technologyQLK2-CT-2001-02377
- DNAa-QLK2-CT-2000-00634
- DNAb-QLK2-CT-2000-00634
- DNAc-QLK2-CT-2000-00634
- DNAg-QLK2-CT-2000-00634
- DomesticQLK2-CT-2001-00879
- DoxpQLK2-CT-2002-00887
- Drug deliveryQLK2-CT-2001-01451
- Drug designQLK2-CT-2000-00109QLK2-CT-2002-00887QLK2-CT-2002-01001QLK2-CT-2002-01682
- Drug developmentQLK2-CT-2000-01761
- Drug discoveryQLK2-CT-2000-01630
- Drug resistanceQLK2-CT-2000-00291QLK2-CT-2000-01761QLK2-CT-2001-02360QLK2-CT-2002-01503
- Drug susceptibilityQLK2-CT-2002-01432
- Drug targetsQLK2-CT-2001-02018
- Drug transportersQLK2-CT-2001-02377
- Drug-resistanceQLK2-CT-2000-01020QLK2-CT-2001-01344QLK2-CT-2002-01311
- Drug-targetsQLK2-CT-2002-01682
- Druggable targetsQLK2-CT-2000-01536
E
- Early lifeQLK2-CT-1999-00429
- EcologyQLK2-CT-2002-01358
- Efficacious deliveryQLK2-CT-2001-01346
- Efflux pumpsQLK2-CT-2001-01339
- EggsQLK2-CT-2002-01546
- EhrlichiaQLK2-CT-2002-01293
- EIF3QLK2-CT-2000-01535
- Electronic databaseQLK2-CT-2001-01810
- Emergency treatmentQLK2-CT-2001-01430
- Emerging infectionQLK2-CT-2002-01293
- Emerging virusesQLK2-CT-1999-01119
- Endotoxin neutralisationQLK2-CT-2002-01001
- Enhanced surveillanceQLK2-CT-2001-01632
- Enteric and respiratory infectionsQLK2-CT-2001-00874
- Enteric diseasesQLK2-CT-2000-00739
- EnterovirusQLK2-CT-2001-01910
- Entry and morphogenesisQLK2-CT-2002-01867
- Epidemiological typingQLK2-CT-2001-01819
- EpidemiologyQLK2-CT-2000-00002QLK2-CT-2000-00600QLK2-CT-2000-01049QLK2-CT-2000-01636QLK2-CT-2000-01709QLK2-CT-2000-01787QLK2-CT-2001-00844QLK2-CT-2001-00879QLK2-CT-2001-00915QLK2-CT-2001-01267QLK2-CT-2001-01339QLK2-CT-2001-01420QLK2-CT-2001-01436QLK2-CT-2001-01441QLK2-CT-2001-01810QLK2-CT-2001-01994QLK2-CT-2001-01995QLK2-CT-2001-02248QLK2-CT-2001-02380QLK2-CT-2002-00722QLK2-CT-2002-01358QLK2-CT-2002-01398QLK2-CT-2002-01573
- Epithelial cellsQLK2-CT-2002-01719
- EpitopeQLK2-CT-2002-00620
- EpitopesQLK2-CT-2001-01167QLK2-CT-2002-01329
- Error catastrophyQLK2-CT-2000-00291
- ErythritolQLK2-CT-2002-00887
- Escherichia coliQLK2-CT-2002-00944
- EuropeQLK2-CT-2001-00879QLK2-CT-2001-01344
- EvolutionQLK2-CT-2001-00873
- Expression_profilesQLK2-CT-2000-01126
- Extraintestinal infections in manQLK2-CT-2002-00944
F
- Familial fatal insomniaQLK2-CT-2000-00837
- Feline immunodeficiency virus (FIV)QLK2-CT-2000-00291
- FingerprintingQLK2-CT-2000-01404
- FishQLK2-CT-2000-01049QLK2-CT-2002-00838QLK2-CT-2002-01691
- Fish diseaseQLK2-CT-2001-00970
- Fish diseasesQLK2-CT-2002-01546
- Fish feedQLK2-CT-2001-01288
- Fish healthQLK2-CT-2002-01546
- Fish virus diagnosisQLK2-CT-2001-00970
- Fish virus epidemiologyQLK2-CT-2001-00970
- Fish virus pathogenesisQLK2-CT-2001-00970
- FitnessQLK2-CT-2002-01311
- FMDVQLK2-CT-2002-01304QLK2-CT-2002-01719
- Foetal deathQLK2-CT-2001-00877
- Food ingested bacteriaQLK2-CT-2002-00843
- Food safetyQLK2-CT-2001-01267
- Foot and mouth diseaseQLK2-CT-2002-01304
- Foot-and-mouth diseaseQLK2-CT-2002-00825
- Formalin-inactivated rsv (FI-RSV)QLK2-CT-1999-01044
- Fungal infectionsQLK2-CT-2000-00795
- Fungal pathogenQLK2-CT-2001-01236
G
- GeneQLK2-CT-2002-00918
- Gene expressionQLK2-CT-2001-01631
- Gene therapyQLK2-CT-2000-01040QLK2-CT-2000-01476
- Gene-flowQLK2-CT-2000-00809
- Genetic crossQLK2-CT-2002-00774
- Genetic immunisationQLK2-CT-1999-00588
- Genetically modified plantsQLK2-CT-2001-01288
- GeneticsQLK2-CT-1999-01093QLK2-CT-2001-01995
- Gene_expressionQLK2-CT-2000-01126
- Genome scanningQLK2-CT-2002-00774
- Genome variabilityQLK2-CT-2001-00977
- GenomicQLK2-CT-1999-01093
- Genomic analysisQLK2-CT-2001-01819
- Genomic transcript profilesQLK2-CT-2000-01536
- GenotypeQLK2-CT-2001-00977
- GenotypingQLK2-CT-2001-01632QLK2-CT-2001-01940
- Gerstmann-sträussler-scheinker diseaseQLK2-CT-2000-00837
- GISQLK2-CT-2000-00611
- GlycodendrimersQLK2-CT-2002-01852
- GlycopolymersQLK2-CT-2002-01852
- GoatsQLK2-CT-2002-00918
- Gram-positive bacteriaQLK2-CT-2000-00336
- GranulomaQLK2-CT-1999-00799
- Gut adhesion moleculesQLK2-CT-2001-01288
- Gyrodactylus salarisQLK2-CT-2001-01631
H
- HaartQLK2-CT-2000-01040QLK2-CT-2000-01431QLK2-CT-2002-01708
- Haemophilus parasuisQLK2-CT-2000-00726
- HantavirusQLK2-CT-1999-01119QLK2-CT-2002-01358
- HBVQLK2-CT-2001-02114
- HBV core particlesQLK2-CT-2000-01476
- HCVQLK2-CT-2000-01535QLK2-CT-2001-01167
- HCV antiviralsQLK2-CT-2002-01079
- HCV cytotoxic epitopesQLK2-CT-1999-00356
- HCV NS3 helicaseQLK2-CT-2002-01079
- HCV quasispeciesQLK2-CT-2002-00954
- HCV replicationQLK2-CT-1999-00356
- HCV repliconsQLK2-CT-2002-00954
- HCV structural proteinsQLK2-CT-1999-00356
- HCV vaccineQLK2-CT-1999-00356
- HelicobacterQLK2-CT-1999-00310
- Helicobacter pyloriQLK2-CT-2001-01216
- Hemorrhagic fever with renal syndromeQLK2-CT-1999-01119
- Heparan mimeticsQLK2-CT-2001-02085
- HeparinQLK2-CT-2001-02085
- Hepatitis A virusQLK2-CT-2000-00542
- Hepatitis B virusQLK2-CT-2000-00542QLK2-CT-2001-00977
- Hepatitis C QLK2-CT-1999-00055
- Hepatitis C - treatmentQLK2-CT-2000-00836
- Hepatitis C virusQLK2-CT-1999-00356QLK2-CT-1999-00588QLK2-CT-2001-01120QLK2-CT-2002-00954
- Hepatitis C virus (HCV)QLK2-CT-2002-01329
- Hepatits C virusQLK2-CT-2002-01079
- HerpesQLK2-CT-1999-00055
- Heterologous antigen deliveryQLK2-CT-1999-00780
- Heterologous vaccinationQLK2-CT-1999-00310
- High throughput screeningQLK2-CT-2000-01624
- High-throughput screeningQLK2-CT-2000-01630QLK2-CT-2002-00892
- High-throughput screening of ampsQLK2-CT-2000-00411
- highly pathogenicQLK2-CT-2002-01454
- HIVQLK2-CT-1999-00609QLK2-CT-2000-00150QLK2-CT-2000-00773QLK2-CT-2000-01431QLK2-CT-2000-01630QLK2-CT-2001-01167QLK2-CT-2001-01344QLK2-CT-2002-01708
- HIV infectionQLK2-CT-2000-00002
- HIV RNA QLK2-CT-2000-01431QLK2-CT-2002-01708
- HIV treatmentQLK2-CT-2000-01040
- HIV vaccineQLK2-CT-1999-00871QLK2-CT-2002-01430
- HIV-1QLK2-CT-2002-01311
- HIV-1 subtypes B & CQLK2-CT-1999-01321QLK2-CT-2001-01316
- HIV-1 vaccinQLK2-CT-2002-01431
- HIV-1/MULV modelQLK2-CT-2002-01430
- HIV-vaccinesQLK2-CT-2002-01299
- HLA class I QLK2-CT-2001-01167
- HLA transgenic mouse modelsQLK2-CT-2002-01329
- Host preferenceQLK2-CT-2001-01420
- HPIV3QLK2-CT-2002-01722
- HPVQLK2-CT-2002-01500
- HRSVQLK2-CT-2002-01722
- HSV-1 pathogenesisQLK2-CT-2002-00810
- Human clinical trialsQLK2-CT-1999-01044
- Human immunodeficiency virusQLK2-CT-2001-02360
- Human immunodeficiency virus (HIV)QLK2-CT-2000-00291
- Human infectious diseaseQLK2-CT-2000-01536
- Human monoclonal antibodiesQLK2-CT-2001-01120
- Human papillomavirusQLK2-CT-2002-01179
- Human parainfluenza virus type 3QLK2-CT-2002-01722
- Human respiratory syncytial virusQLK2-CT-2002-01722
I
- IdentificationQLK2-CT-2000-01404
- Identification of new classes of antimicrobialsQLK2-CT-2001-01200
- IimmunityQLK2-CT-2001-00877
- Immune responseQLK2-CT-2000-01049QLK2-CT-2001-01631QLK2-CT-2002-00825
- Immune responsesQLK2-CT-2002-00617
- Immune stimulatorsQLK2-CT-2000-00336
- Immune systemQLK2-CT-2001-01924
- Immune therapyQLK2-CT-2000-01040QLK2-CT-2000-01476
- ImmunityQLK2-CT-1999-00014QLK2-CT-1999-01093QLK2-CT-2000-00542QLK2-CT-2002-01432
- Immunity-driven selectionQLK2-CT-2001-01819
- ImmunocomplexQLK2-CT-2002-01050
- ImmunocompromisedQLK2-CT-2001-00877
- Immunogen carrierQLK2-CT-1999-00318
- ImmunogenicityQLK2-CT-2001-01786QLK2-CT-2002-01613
- ImmunogensQLK2-CT-2002-01329
- immunological correlatesQLK2-CT-1999-01044
- Immunological reagentsQLK2-CT-2002-00838
- Immunological responsesQLK2-CT-1999-00799
- ImmunologyQLK2-CT-1999-00359QLK2-CT-2000-00836QLK2-CT-2002-00722QLK2-CT-2002-01399
- Immunomodulatory moleculesQLK2-CT-1999-00601
- Immunomodulatory proteinsQLK2-CT-2002-01867
- ImmunopathologyQLK2-CT-1999-01044QLK2-CT-1999-01215QLK2-CT-2002-00882
- ImmunoprotectionQLK2-CT-2001-00874
- ImmunotherapeuticsQLK2-CT-2002-01329
- ImmunotherapyQLK2-CT-2002-01628
- ImmunpathologyQLK2-CT-2002-01329
- In vitro encapsidation of nucleic acidsQLK2-CT-2000-01476
- In-ovo vaccinationQLK2-CT-1999-00601
- Individualized treatmentQLK2-CT-2000-00836
- Induction of protectionQLK2-CT-2001-01374
- InfectionQLK2-CT-2000-00325QLK2-CT-2002-01613QLK2-CT-2002-01628
- Infection controlQLK2-CT-2001-00915
- InfectionsQLK2-CT-2001-01994
- Infectious diseaseQLK2-CT-2000-00589
- Infectious diseasesQLK2-CT-1999-00429QLK2-CT-2001-02103QLK2-CT-2002-01691
- Infectious salmon anaemia virusQLK2-CT-2001-00844
- InflammationQLK2-CT-2000-00325
- Inflammatory cytokinesQLK2-CT-1999-00799
- InfluenzaQLK2-CT-2002-01034
- Influenza virusQLK2-CT-2001-01786
- InhibitorQLK2-CT-2002-01250
- Inhibitor designQLK2-CT-2001-02360
- InhibitorsQLK2-CT-2000-01166QLK2-CT-2002-01682
- Innate immune responseQLK2-CT-2001-01374
- Innate immunityQLK2-CT-2000-00336QLK2-CT-2001-01216QLK2-CT-2001-02103QLK2-CT-2002-00846QLK2-CT-2002-01691
- Inter-species transmissionQLK2-CT-2001-01420
- InterferonQLK2-CT-2001-02114QLK2-CT-2002-00846QLK2-CT-2002-00954
- International databasesQLK2-CT-2001-01940
- Intervention to reduce resistanceQLK2-CT-2000-01020
- Intervention vaccinationQLK2-CT-2001-01346
- InterventionsQLK2-CT-2000-00002
- Intestinal microbiotaQLK2-CT-2002-00843
- IntiminQLK2-CT-2000-00600
- Invasive infectionsQLK2-CT-2002-01398
- IresQLK2-CT-2000-01535
- IscomQLK2-CT-1999-00772QLK2-CT-2002-01034
- IsoprenoidQLK2-CT-2002-00887
J
- JaagsiekteQLK2-CT-2001-02380
K
- KetolideQLK2-CT-2000-00935
- Key mutationsQLK2-CT-2002-01708
- Killer ig-like receptorsQLK2-CT-2002-01112
- Knockout miceQLK2-CT-2002-00846
- Knowledge enginesQLK2-CT-2000-01020
L
- Laboratory diagnosisQLK2-CT-2000-00294
- Lactococcus garvieaeQLK2-CT-2000-01049
- Land coverQLK2-CT-2000-01787
- Land use changeQLK2-CT-2000-01787
- Laser micro-dissectionQLK2-CT-2002-01719
- Laser microdissectionQLK2-CT-2002-00954
- Latent-tuberculosisQLK2-CT-2002-01682
- Lectin-like receptorsQLK2-CT-2002-01112
- Leishmania donovaniQLK2-CT-2001-01404
- Leishmania infantumQLK2-CT-2001-01810
- LeishmaniasisQLK2-CT-2001-01404
- LentivirusQLK2-CT-2002-00617
- Life cycleQLK2-CT-2002-00722
- Lipid anchorsQLK2-CT-1999-00772
- LipopeptidesQLK2-CT-1999-00772QLK2-CT-2002-01001
- LipopolysaccharideQLK2-CT-2002-00918
- Live attenuated vaccineQLK2-CT-1999-01215
- Live oral carrierQLK2-CT-1999-00310
- Liver stageQLK2-CT-2001-01886
- LPSQLK2-CT-2000-00336
- LungQLK2-CT-2000-00325
- Lung tumourQLK2-CT-2001-02380
- Lymph nodeQLK2-CT-1999-01215QLK2-CT-2002-00882
- Lysis ligandsQLK2-CT-2002-01112
M
- MacrolideQLK2-CT-2000-00935
- MacrophagesQLK2-CT-2001-02103QLK2-CT-2002-00846
- Major histocompatibility complex (mhc)QLK2-CT-2002-00620
- MalariaQLK2-CT-1999-00753QLK2-CT-1999-01293QLK2-CT-2000-00109QLK2-CT-2000-01787QLK2-CT-2001-01167QLK2-CT-2001-01302QLK2-CT-2002-00774QLK2-CT-2002-01503
- Malaria chemotherapyQLK2-CT-2000-01166
- Mannosylated protein mp65QLK2-CT-2001-01216
- Marek`s diseaseQLK2-CT-1999-00601
- Marked vaccineQLK2-CT-2002-00825
- MDR regulatory networkQLK2-CT-2001-02377
- MDR-TBQLK2-CT-2002-01612
- MDVQLK2-CT-1999-00601
- MeaslesQLK2-CT-2000-00542QLK2-CT-2001-01632
- Measles virusQLK2-CT-2001-01225
- MechanismsQLK2-CT-2000-00809
- Membrane mimeticsQLK2-CT-2002-01001
- MeningitisQLK2-CT-1999-00359
- MEPQLK2-CT-2002-00887
- MetapneumovirusQLK2-CT-2002-01699
- MethylQLK2-CT-2002-00887
- MHCQLK2-CT-2002-00838
- MicroarrayQLK2-CT-2000-01126
- MicroarraysQLK2-CT-2000-00726QLK2-CT-2002-00954
- Microbial adhesionQLK2-CT-2001-01216
- Microbial diversityQLK2-CT-2000-01404
- Microbial extractsQLK2-CT-2002-00892
- MicrosatellitesQLK2-CT-2001-01810
- MiltefosineQLK2-CT-2001-01404
- Modified live vaccinesQLK2-CT-1999-00601
- Modified vaccinia virus ankara (MVA)QLK2-CT-1999-01044
- Modular systemQLK2-CT-2002-01722
- Molecular biologyQLK2-CT-2000-00726QLK2-CT-2001-00844QLK2-CT-2002-01699
- Molecular biology methodsQLK2-CT-2000-00765
- Molecular diagnosticsQLK2-CT-2002-01500
- Molecular epidemiologyQLK2-CT-2000-00630QLK2-CT-2000-01404QLK2-CT-2001-01050QLK2-CT-2001-01722QLK2-CT-2001-02216
- Molecular fingerprinting of drug-resistant pneumococcal clonesQLK2-CT-2000-01020
- Molecular geneticsQLK2-CT-2000-01761QLK2-CT-2001-01267
- Molecular markersQLK2-CT-2000-00611
- Molecular techniquesQLK2-CT-2000-00294
- Molecular toolsQLK2-CT-2000-01787
- Molecular typingQLK2-CT-2001-01810QLK2-CT-2002-01398QLK2-CT-2002-01612
- MonitoringQLK2-CT-2002-01146
- MononegaviralesQLK2-CT-2001-01225
- MorphogenesisQLK2-CT-2000-00795
- MortalityQLK2-CT-2000-00589
- MosquitoQLK2-CT-2000-01787
- Mother-to-child transmissionQLK2-CT-2000-00002
- Mouse and pig model of infectionQLK2-CT-1999-00780
- Mucosal deliveryQLK2-CT-2002-01722
- Mucosal immunityQLK2-CT-1999-00367QLK2-CT-1999-00983QLK2-CT-1999-01215QLK2-CT-2002-00882
- Mucosal infection modelQLK2-CT-1999-00601
- Mucosal vaccinationQLK2-CT-1999-00367
- Multi drug resistanceQLK2-CT-2002-01612
- Multi-drug resistanceQLK2-CT-2000-00765QLK2-CT-2002-00774
- Multidrug resistanceQLK2-CT-2000-00630
- Multidrug resistance (mdr)QLK2-CT-2001-02377
- Multilocus sequence typingQLK2-CT-2001-01436
- Multiple drug resistanceQLK2-CT-2001-01940
- Multiple epitopesQLK2-CT-1999-00318
- Multiplex reactionsQLK2-CT-2000-00294
- Multiplex real-time pcrQLK2-CT-2000-00486
- Multiresistant bacteriaQLK2-CT-2000-00411
- Multiresistant micro-organismsQLK2-CT-2002-00892
- MultivalencyQLK2-CT-2002-01852
- MumpsQLK2-CT-2000-00542
- MutantQLK2-CT-2002-00918
- MutatorQLK2-CT-2001-00873
- MVAQLK2-CT-2002-01034QLK2-CT-2002-01329
- Mycobacterium avium subsp. paratuberculosisQLK2-CT-2001-01420
- Mycobacterium tuberculosisQLK2-CT-2002-00846QLK2-CT-2002-00887
- Mycolic acid pathwayQLK2-CT-2001-02018
- Mycoplasma pneumoniaeQLK2-CT-2002-01050
- Myxidium leeiQLK2-CT-2002-00722
- MyxozoaQLK2-CT-2002-00722
N
- NefQLK2-CT-2000-01630
- Neisseria meningitidisQLK2-CT-1999-00359QLK2-CT-2001-01436
- NeonatalQLK2-CT-1999-00429
- NeonateQLK2-CT-2002-01249
- Neospora caninumQLK2-CT-2001-01050
- Nervous systemQLK2-CT-2002-01628
- NeurodegenerationQLK2-CT-2000-00837QLK2-CT-2002-01523
- New molecular methodsQLK2-CT-2001-01819
- NK cellsQLK2-CT-2002-01112
- Non-human primatesQLK2-CT-1999-00871
- Non-liveQLK2-CT-1999-00318
- Non-melanoma skin cancerQLK2-CT-2002-01500
- Non-replicatingQLK2-CT-1999-00318
- Nonnucleoside reverse transcriptase inhibitors (NNRTIS)QLK2-CT-2000-00291
- Novel antibioticsQLK2-CT-2002-01001
- Novel inhibitor compoundsQLK2-CT-2000-01535
- Novel type marker vaccinesQLK2-CT-2001-01346
- Novel vaccinesQLK2-CT-1999-00983
- Nucleic acidQLK2-CT-1999-00459
- NucleocapsidQLK2-CT-2001-01225
- Nucleoside rt inhibitors (NRTIS)QLK2-CT-2000-00291
- NYVACQLK2-CT-2002-01431
- NYVAC- MVA - elispotQLK2-CT-2002-01299
O
- Observational studyQLK2-CT-2000-00773
- Oral fluid testingQLK2-CT-2001-01632
- Oral vaccinationQLK2-CT-1999-00780QLK2-CT-2001-01288
- OrganophosphatesQLK2-CT-2000-00809
- Ornithodoros erraticusQLK2-CT-2001-02216
- Outer membrane vesicleQLK2-CT-1999-00359
- Ovine pulmonary adenocarcinomaQLK2-CT-2001-02380
- Oxidative stressQLK2-CT-2001-01924
P
- P. falciparumQLK2-CT-2001-01886
- PaediatricQLK2-CT-2000-00002
- Palmitoyl estersQLK2-CT-1999-00772
- PandemicsQLK2-CT-2001-01786
- PapillomavirusQLK2-CT-1999-00055
- ParamyxovirusQLK2-CT-2002-01699
- ParapoxQLK2-CT-1999-00459
- ParatuberculosisQLK2-CT-2001-00879QLK2-CT-2001-01420
- Particulate structureQLK2-CT-1999-00318
- ParvovirusQLK2-CT-2001-00877
- PathogenQLK2-CT-2002-01546
- PathogenesisQLK2-CT-1999-00307QLK2-CT-1999-00938QLK2-CT-2000-00600QLK2-CT-2000-00726QLK2-CT-2002-01867
- Pathogenetic mechanismsQLK2-CT-2000-01049
- PathogenicityQLK2-CT-2001-01631QLK2-CT-2002-01311QLK2-CT-2002-01329QLK2-CT-2002-01454
- PathologyQLK2-CT-2001-01267
- PCRQLK2-CT-2001-02380QLK2-CT-2002-00722QLK2-CT-2002-01432
- PepscanQLK2-CT-1999-00772
- PeptideQLK2-CT-1999-00854
- Peptide carrierQLK2-CT-2001-01451
- Peptide vaccinesQLK2-CT-2002-00838
- PeptidesQLK2-CT-2001-01167QLK2-CT-2002-00620
- Peptidoglygan binding proteinQLK2-CT-2000-00336
- PersistenceQLK2-CT-2002-01719
- PertussisQLK2-CT-2000-00542
- Pharmacokinetic studiesQLK2-CT-2000-00150
- PharmacokineticsQLK2-CT-2002-01432
- Phase i hiv vaccine trialQLK2-CT-1999-01321QLK2-CT-2001-01316
- Phase iia clinical trialQLK2-CT-2002-01431
- PhenotypeQLK2-CT-2001-00977
- Phenotypic switchingQLK2-CT-2000-00795
- PheromoneQLK2-CT-2001-01236
- PhosphateQLK2-CT-2002-00887
- PhospholipidQLK2-CT-2000-01166
- Phospholipid metabolismQLK2-CT-2000-01166
- phylogenetic analysisQLK2-CT-2001-01810
- PhylogenyQLK2-CT-2002-01699
- PigsQLK2-CT-1999-00002QLK2-CT-2000-00726QLK2-CT-2002-01304
- Plant expression systemsQLK2-CT-2002-01050
- PlantibodiesQLK2-CT-2000-00739
- Plasmodium falciparumQLK2-CT-2000-01166
- Plasmodium vivaxQLK2-CT-2000-01166
- Plum pox potyvirusQLK2-CT-2000-00739
- Pneumococcal-carriageQLK2-CT-2000-01020
- Pneumocystis carinii epidemiologyQLK2-CT-2000-01369
- Pneumocystis carinii genotypesQLK2-CT-2000-01369
- Pneumocystis carinii immunologyQLK2-CT-2000-01369
- Pneumocystis carinii phenotypic characterisationQLK2-CT-2000-01369
- PolymorphismQLK2-CT-2001-01819
- PolysaccharideQLK2-CT-1999-00854
- Population biologyQLK2-CT-2001-01436
- Population changesQLK2-CT-2000-00611
- Population geneticsQLK2-CT-2001-01810
- PorcineQLK2-CT-1999-00445
- Porcine circovirus (pcv)QLK2-CT-2002-01050
- Porcine reproductive and respiratory syndrome virus (prrsv)QLK2-CT-2002-01050
- PoultryQLK2-CT-1999-00002QLK2-CT-2002-01454
- Pre-clinical development of vaccineQLK2-CT-1999-00228
- Pre-clinical development of vaccinesQLK2-CT-1999-00070
- Pre-clinical evaluationQLK2-CT-2002-01329
- Pre-clinical studiesQLK2-CT-2002-01001
- Predictive modellingQLK2-CT-2000-00611
- PregnancyQLK2-CT-2001-00877QLK2-CT-2001-01302
- PrevalenceQLK2-CT-2001-01050
- PreventionQLK2-CT-2000-01761QLK2-CT-2001-01344
- Primary immunodeficiencyQLK2-CT-2002-00846
- Primary resistanceQLK2-CT-2002-01708
- Prime-boostQLK2-CT-2002-01430QLK2-CT-2002-01431
- Prime-boost hiv vaccineQLK2-CT-1999-01321QLK2-CT-2001-01316
- PrionQLK2-CT-2000-00837QLK2-CT-2001-02085
- Prion animal modelsQLK2-CT-2001-02085
- Prion diseasesQLK2-CT-2000-00837QLK2-CT-2002-01523
- Prion proteinQLK2-CT-2001-01924
- PrionsQLK2-CT-2002-01628
- ProgressionQLK2-CT-2000-01431QLK2-CT-2002-01708
- ProteaseQLK2-CT-2002-01250
- Protease inhibitorQLK2-CT-2001-02360
- ProteasomeQLK2-CT-2001-01167
- Protein and nucleotide kinasesQLK2-CT-2001-02018
- Protein structureQLK2-CT-2001-02018
- Protein synthesisQLK2-CT-2002-00892
- Protein vaccineQLK2-CT-2002-01430
- Proteolytic cleavageQLK2-CT-1999-00772
- Proteome expression profilesQLK2-CT-2000-01536
- ProteomicsQLK2-CT-2000-01536
- Proteomics and linkage mapsQLK2-CT-2001-02018
- Pseudomonas aeruginosaQLK2-CT-2001-01339
- Public healthQLK2-CT-2000-01369QLK2-CT-2000-01787QLK2-CT-2001-01995
- Pulmonary adenomatosisQLK2-CT-2001-02380
- Pulmonary tumourQLK2-CT-1999-00983
- PyrethroidsQLK2-CT-2000-00809
Q
- Quality assuranceQLK2-CT-2000-00294
- Quantitative pcr/rt-pcrQLK2-CT-1999-00983
R
- Rainbow troutQLK2-CT-2001-01288
- Rapid onset immunityQLK2-CT-2001-01346
- Rational design & deliveryQLK2-CT-1999-00459
- Rational design of ampsQLK2-CT-2000-00411
- Rational design of inhibitorsQLK2-CT-2001-02018
- Rational inhibitor designQLK2-CT-2002-00892
- ReagentsQLK2-CT-1999-00609
- Real time nasbaQLK2-CT-2000-00294
- Real time pcrQLK2-CT-2000-00294
- Reccombinant attenuated pox virusQLK2-CT-2002-01299
- Recombinant antibodiesQLK2-CT-2000-00739
- ReductoisomeraseQLK2-CT-2002-00887
- Remote sensingQLK2-CT-2000-01787
- Replication capacityQLK2-CT-2002-01311
- Replication-deficientQLK2-CT-2002-01722
- ResistanceQLK2-CT-2000-00809QLK2-CT-2001-00873QLK2-CT-2001-00915QLK2-CT-2001-01631QLK2-CT-2002-01612
- ResistanceQLK2-CT-2001-01404
- Respiratory syncytial virusQLK2-CT-2001-01225
- Respiratory syncytial virus (RSV)QLK2-CT-1999-01044
- RetrovirusQLK2-CT-1999-00983
- RetrovirusesQLK2-CT-2001-02380
- Reverse geneticsQLK2-CT-2001-01786QLK2-CT-2002-01699
- Reverse transcriptaseQLK2-CT-2000-00291QLK2-CT-2002-01311
- ReversibilityQLK2-CT-2001-00873
- ReversionQLK2-CT-2001-01722
- RibavirinQLK2-CT-2001-01225QLK2-CT-2002-01432
- RibosomeQLK2-CT-2000-00935
- RibosomesQLK2-CT-2002-00892
- RibotypingQLK2-CT-2000-01404
- RickettsiaQLK2-CT-2002-01293
- RifampicinQLK2-CT-2000-00765
- Risk assessmentQLK2-CT-2000-00611QLK2-CT-2001-01441QLK2-CT-2002-01546
- Risk factorsQLK2-CT-2001-01050QLK2-CT-2001-01994
- Risk managementQLK2-CT-2002-01546
- Risk mapsQLK2-CT-2000-00611
- RNAQLK2-CT-2000-01535
- RNA-basedQLK2-CT-2002-01722
- RNA-dependent RNA-polymeraseQLK2-CT-2001-01225
- RodentsQLK2-CT-2002-01358
- RotavirusQLK2-CT-2001-00874QLK2-CT-2001-01216QLK2-CT-2002-00846QLK2-CT-2002-01249
- RoughQLK2-CT-2002-00918
- RRNAQLK2-CT-2000-00935
- RT-FHIVQLK2-CT-2000-00291
- RT-PCRQLK2-CT-2001-01632
- RuminantsQLK2-CT-2001-00879
S
- Saccharomyces cerevisiaeQLK2-CT-2001-02377
- SafetyQLK2-CT-2002-01613
- Salmon pancrease diseaseQLK2-CT-2001-00970
- SalmonellaQLK2-CT-1999-00310
- SalmonellasQLK2-CT-2001-01940
- Salmonella_typhimuriumQLK2-CT-2000-01126
- Salmonid alphavirusQLK2-CT-2001-00970
- Sar studiesQLK2-CT-2002-01001
- Satellite imageryQLK2-CT-2000-00611
- Screening systemQLK2-CT-2001-02377
- SealiceQLK2-CT-2000-00809
- Secreted aspartyl proteinasesQLK2-CT-2000-00795
- SemiochemicalQLK2-CT-2001-01236
- Sendai virusQLK2-CT-2001-01225
- Sensor arrayQLK2-CT-2000-00765
- SepsisQLK2-CT-2000-00589QLK2-CT-2002-01001
- Septic shockQLK2-CT-2000-00589
- Sequence databaseQLK2-CT-2002-01329
- Sero-epidemiologyQLK2-CT-2000-00542
- SeroconvertersQLK2-CT-2000-01431QLK2-CT-2002-01708
- Serological assaysQLK2-CT-2002-01500
- Severe malariaQLK2-CT-2001-01430
- SFVQLK2-CT-2002-01431
- SFV/DNA vaccineQLK2-CT-2001-01316
- SheepQLK2-CT-1999-00983QLK2-CT-2001-02380QLK2-CT-2002-00918QLK2-CT-2002-01304
- ShigellosisQLK2-CT-1999-00938
- Shiv modelQLK2-CT-2002-01430
- Signal transductionQLK2-CT-2000-00543QLK2-CT-2002-00954
- Sindbis virus vaccinesQLK2-CT-1999-00601
- Single nucleotide polymorphismsQLK2-CT-2002-01612
- Skin cancerQLK2-CT-2002-01179
- Sleeping diseaseQLK2-CT-2001-00970
- SLT-VTQLK2-CT-2000-00600
- Small immunoproteinsQLK2-CT-2000-00739
- Small ruminantQLK2-CT-2002-00617
- SNPQLK2-CT-2002-01612
- Socio-economicsQLK2-CT-2002-01573
- SparidaeQLK2-CT-2002-00722
- SpermQLK2-CT-2002-01546
- Spike proteinQLK2-CT-2002-01050
- SporulationQLK2-CT-2001-01267
- SPS agreementQLK2-CT-2002-01546
- ST2QLK2-CT-2002-00846
- StabilityQLK2-CT-2002-00843
- Stage-specific antigensQLK2-CT-2001-01050
- StandardizationQLK2-CT-2000-01404
- StaphylococcusQLK2-CT-2002-01250
- Strain selectionQLK2-CT-2002-01034
- Strain-specific markersQLK2-CT-2001-01420
- Streptococcal infectionsQLK2-CT-2000-01049
- Streptococcus gordoniiQLK2-CT-2001-01216
- Streptococcus iniaeQLK2-CT-2000-01049
- Streptococcus pneumoniaeQLK2-CT-2000-00543
- Streptococcus pyogenesQLK2-CT-2002-01398
- Structural biologyQLK2-CT-2001-01339
- Structure of lipopeptidesQLK2-CT-1999-00772
- Structure-function analysisQLK2-CT-2000-01630QLK2-CT-2002-00620
- Sub-typeQLK2-CT-2000-01431QLK2-CT-2002-01708
- Subcellular antigen targetingQLK2-CT-1999-00780
- Subunit vaccinesQLK2-CT-1999-01044
- SuppositoryQLK2-CT-2001-01430
- Surface displayQLK2-CT-1999-00854
- SurfactantQLK2-CT-2000-00325
- SurveillanceQLK2-CT-2000-01636QLK2-CT-2001-01344QLK2-CT-2001-01441QLK2-CT-2001-01786QLK2-CT-2001-02248
- SurvivalQLK2-CT-2000-01431QLK2-CT-2002-01708
- Susceptibility testingQLK2-CT-2002-01146
- SVCQLK2-CT-2001-01288
- SwineQLK2-CT-1999-00307
- Swine influenzaQLK2-CT-2000-01636
- Swine virusesQLK2-CT-2000-00486
- Synthetic vaccinesQLK2-CT-1999-00772
T
- T cell immunityQLK2-CT-2002-00700
- T cellsQLK2-CT-1999-00588
- T-cell immunologyQLK2-CT-1999-00367
- T-helper cellsQLK2-CT-2000-01040
- TapQLK2-CT-2001-01167
- TaxonomyQLK2-CT-2001-01267
- TeflubenzuronQLK2-CT-2000-00809
- Test systems for chicken cytokinesQLK2-CT-1999-00601
- TetramersQLK2-CT-2002-00620
- TH1 cytokinesQLK2-CT-2000-01476
- Therapeutic agentQLK2-CT-2000-00325
- Therapeutic vaccinesQLK2-CT-2002-01329
- TherapeuticsQLK2-CT-2001-01924
- ThymusQLK2-CT-1999-01215QLK2-CT-2002-00882
- Tick borne diseasesQLK2-CT-2002-01293
- Toll-like receptorsQLK2-CT-2000-00336QLK2-CT-2002-00846
- ToxinsQLK2-CT-2001-01267
- TradeQLK2-CT-2002-01546
- Transcript profilingQLK2-CT-2000-00795
- TranscriptionQLK2-CT-2002-00954
- Transcription factorsQLK2-CT-2001-02377
- Transdisease vaccinologyQLK2-CT-1999-00070QLK2-CT-1999-00228
- TransferabilityQLK2-CT-2002-00843
- Transgenic mouseQLK2-CT-1999-00588
- Transgenic plantsQLK2-CT-2000-00739
- Translation inhibitorsQLK2-CT-2002-00892
- TranslocationQLK2-CT-2001-01451
- Transmissible spongiform encephalopathiesQLK2-CT-2000-00837QLK2-CT-2002-01523
- TransmissionQLK2-CT-1999-00753QLK2-CT-2001-01344
- TransplantationQLK2-CT-2002-01432
- TrapQLK2-CT-2001-01236
- TreatmentQLK2-CT-2000-01761
- Treatment regimesQLK2-CT-2001-00873
- TropismQLK2-CT-2002-01719
- TSEQLK2-CT-2001-02085QLK2-CT-2002-01399
- TuberculosisQLK2-CT-1999-00367QLK2-CT-1999-01093QLK2-CT-2000-00630QLK2-CT-2000-00765QLK2-CT-2000-01761QLK2-CT-2002-01612QLK2-CT-2002-01613
- Two-component systemsQLK2-CT-2000-00543
- Type III secretionQLK2-CT-2000-00600
- Type III secretion systemQLK2-CT-1999-00780
- TypingQLK2-CT-2000-01404
U
- UV-radiationQLK2-CT-2002-01179
V
- VaccinationQLK2-CT-1999-00799QLK2-CT-1999-01044QLK2-CT-2000-01049QLK2-CT-2001-01374QLK2-CT-2001-01886QLK2-CT-2002-01399
- VaccineQLK2-CT-1999-00002QLK2-CT-1999-00014QLK2-CT-1999-00307QLK2-CT-1999-00359QLK2-CT-1999-00367QLK2-CT-1999-00445QLK2-CT-1999-00588QLK2-CT-1999-00609QLK2-CT-1999-00854QLK2-CT-1999-00938QLK2-CT-1999-01093QLK2-CT-1999-01293QLK2-CT-2000-00542QLK2-CT-2001-01302QLK2-CT-2001-01910QLK2-CT-2001-02114QLK2-CT-2002-00620QLK2-CT-2002-00918QLK2-CT-2002-01034QLK2-CT-2002-01249QLK2-CT-2002-01613QLK2-CT-2002-01719QLK2-CT-2002-01722
- Vaccine carrierQLK2-CT-1999-00310
- Vaccine developmentQLK2-CT-1999-01119
- Vaccine networkQLK2-CT-1999-00871
- Vaccine testingQLK2-CT-2001-01722
- VaccinesQLK2-CT-1999-00055QLK2-CT-1999-00429QLK2-CT-1999-00459QLK2-CT-1999-00753QLK2-CT-2000-01536QLK2-CT-2001-00874QLK2-CT-2001-01120QLK2-CT-2001-01267QLK2-CT-2001-01786QLK2-CT-2002-01867
- Vaccines/vaccinationQLK2-CT-2001-01819
- Vaccinia virus MVAQLK2-CT-2002-01867
- Vaccinia virus recombinant vaccine vectorsQLK2-CT-1999-01321
- Variant creutzfeldt-jakob diseaseQLK2-CT-2001-01441QLK2-CT-2001-02248
- Variant creutzfeldt-jakob disease surveillanceQLK2-CT-2000-01709
- VariantsQLK2-CT-2001-00977
- Varicella zoster virusQLK2-CT-2000-00542
- VectorQLK2-CT-2001-00874QLK2-CT-2002-00825
- Vector ecologyQLK2-CT-2000-01787
- Vector identificationQLK2-CT-2000-00611
- Vector optimizationQLK2-CT-2002-01867
- Vector passageQLK2-CT-2001-01722
- VectorsQLK2-CT-1999-00002QLK2-CT-1999-00055
- VHSQLK2-CT-2001-01288
- Viral challengesQLK2-CT-2001-01288
- Viral diseaseQLK2-CT-2002-00825
- Viral fitnessQLK2-CT-2001-02360
- Viral fusionQLK2-CT-2002-00810
- Viral g proteinsQLK2-CT-2001-01288
- Viral genesQLK2-CT-2001-02216
- Viral infectionsQLK2-CT-2002-00838QLK2-CT-2002-01691
- Viral loadQLK2-CT-1999-01215QLK2-CT-2002-00882
- Viral particlesQLK2-CT-2002-01329
- Viral persistenceQLK2-CT-2002-01329
- Viral targetsQLK2-CT-2002-01329
- VirologyQLK2-CT-2000-00773QLK2-CT-2000-00836
- VirosomesQLK2-CT-2002-01329
- VirulenceQLK2-CT-2002-00843QLK2-CT-2002-01311
- Virulence factorsQLK2-CT-2000-00795QLK2-CT-2000-01049QLK2-CT-2001-01339
- VirusQLK2-CT-1999-00445QLK2-CT-2002-01500
- Virus detectionQLK2-CT-2002-01329
- Virus loadQLK2-CT-2002-00617
- Virus pseudotypingQLK2-CT-2001-01120
- Virus receptorsQLK2-CT-2001-01120
- Virus vectorQLK2-CT-2000-00739
- Virus-cellsQLK2-CT-2001-02216
- Virus-induced genesQLK2-CT-2002-01691
- Virus-like particlesQLK2-CT-2000-01476
- VLPQLK2-CT-2002-01249
W
- WastingQLK2-CT-1999-00445
- WildlifeQLK2-CT-2001-00879
X
- XenotransplantationQLK2-CT-1999-00307
- XyluloseQLK2-CT-2002-00887
Y
- Yellow fever virus expression vectorsQLK2-CT-2002-01329
- YersiniaQLK2-CT-1999-00780
Z
- Zoo-sanitaryQLK2-CT-2002-01546
- ZoonosisQLK2-CT-2000-00600QLK2-CT-2001-01995QLK2-CT-2002-00944